Literature DB >> 30085298

Safety and efficacy of attenuated classic and variant 2 infectious bronchitis virus candidate vaccines.

Ahmed Ali1, Walid H Kilany2, Mohamed A Zain El-Abideen2, Magdy El Sayed3,4, Magdy Elkady1.   

Abstract

Vaccination programs against infectious bronchitis virus (IBV) in Egypt depend on both classical and/or imported variant IBV strain vaccines. However, many IBV outbreaks associated with respiratory distress, nephropathy, and high mortalities were attributed to the circulation of both classical and new nephropathogenic IBV variant 2 strains. In the present study, we report the development of attenuated IBV candidate vaccines using the classic IBV strains (IBM41 and IB2) and a nephropathogenic strain (IBvar2). The wild-type (WT) viruses were attenuated through serial passages in embryonated specific pathogen free (SPF) chicken eggs. Virulence of the attenuated viruses was then tested via the ocular route inoculation and the in vivo back passage in day-old SPF chickens. Efficacy against homologous challenge was investigated also in day-old SPF chickens. Results showed that the viruses were successfully adapted to the embryo by the 100th (IBM41 and IB2) and 110th passages (IBvar2). The attenuated viruses were safe and showed no change of virulence in day-old SPF chickens up to the 10th back passages. The efficacy experiment showed that the attenuated vaccines showed 90 to 100% protection against the homologous challenge based on ciliostasis score and protection percent. The att-IBM41 and att-IB2 vaccines were able to reduce the shedding of the challenge at 3 days post-infection (DPI) and no virus shedding was detected in both vaccinated groups by 5 DPI. In the att-IBvar2 vaccinated birds, only 20% of vaccinated birds shed the challenge virus with low titers (102.10±0.3 EID50/mL) at 3 DPI. In conclusion, the attenuated strains IBM41, IB2, and IBvar2 are efficient vaccine candidates against currently circulating classic and variant IB viruses, respectively. Further studies to evaluate the field efficacy and combining these attenuated IBV strains to induce a wider protection against heterologous IBV challenge are suggested.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30085298     DOI: 10.3382/ps/pey312

Source DB:  PubMed          Journal:  Poult Sci        ISSN: 0032-5791            Impact factor:   3.352


  7 in total

1.  Protective Efficacy of Different Live Attenuated Infectious Bronchitis Virus Vaccination Regimes Against Challenge With IBV Variant-2 Circulating in the Middle East.

Authors:  Hesham A Sultan; Ahmed Ali; Wael K El Feil; Abdel Hamid I Bazid; Mohamed A Zain El-Abideen; Walid H Kilany
Journal:  Front Vet Sci       Date:  2019-10-09

2.  Epidemiological investigation of avian infectious bronchitis and locally determined genotype diversity in central China: a 2016-2018 study.

Authors:  Jun Ji; Yuyun Gao; Qinxi Chen; Qianqian Wu; Xin Xu; Yunchao Kan; Lunguang Yao; Yingzuo Bi; Qingmei Xie
Journal:  Poult Sci       Date:  2020-04-10       Impact factor: 3.352

Review 3.  The emergence, evolution and spread of infectious bronchitis virus genotype GI-23.

Authors:  Mohamed H Houta; Kareem E Hassan; Azza A El-Sawah; Magdy F Elkady; Walid H Kilany; Ahmed Ali; Ahmed S Abdel-Moneim
Journal:  Arch Virol       Date:  2021-01-08       Impact factor: 2.574

Review 4.  Towards Improved Use of Vaccination in the Control of Infectious Bronchitis and Newcastle Disease in Poultry: Understanding the Immunological Mechanisms.

Authors:  Anthony C Ike; Chukwuebuka M Ononugbo; Okechukwu J Obi; Chisom J Onu; Chinasa V Olovo; Sophia O Muo; Okoro S Chukwu; Eleazar E Reward; Odinakachukwu P Omeke
Journal:  Vaccines (Basel)       Date:  2021-01-04

5.  The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines.

Authors:  Anwar A G Al-Kubati; Maged Gomaa Hemida; Abdullah I A Al-Mubarak
Journal:  Virusdisease       Date:  2022-08-29

6.  Distribution and molecular characterization of avian infectious bronchitis virus in southern China.

Authors:  Jiamin Lian; Zhanxin Wang; Zhouyi Xu; Tong Chen; Guanming Shao; Xinheng Zhang; Jianping Qin; Qingmei Xie; Wencheng Lin
Journal:  Poult Sci       Date:  2021-03-27       Impact factor: 3.352

7.  One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-CoV-2.

Authors:  Anna D J Korath; Jozef Janda; Eva Untersmayr; Milena Sokolowska; Wojciech Feleszko; Ioana Agache; Ahmed Adel Seida; Katrin Hartmann; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Allergy       Date:  2021-07-09       Impact factor: 14.710

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.